The Global Dementia Drugs Market Size accounted for USD 15.5 Billion in 2021 and is estimated to garner a market size of USD 32.3 Billion by 2030 rising at a CAGR of 8.7% from 2022 to 2030. Increasing number of patients suffering from chronic diseases is the primary factor boosting the global dementia drugs market value. In addition, high government spending on drug development is another factor that is fueling the dementia drugs industry growth. Furthermore, key players focus on introduction of innovative solutions is one of the popular dementia drug market trends that are flourishing the industry growth in the coming years.

Dementia Drugs Market Report Key Highlights

• Global dementia drugs market revenue is estimated to reach USD 32.3 Billion by 2030 with a CAGR of 8.7% from 2022 to 2030
• According to the World Health Organization, over 55 million people suffer from dementia in the world
• North America dementia drugs market conquered more than 35% regional shares in 2021
• Asia-Pacific dementia drugs market will achieve a noteworthy CAGR from 2022 to 2030
• Based on drug class segment, MAO inhibitors acquired more than 45% of the total market share in 2021
• Growing incidences of Alzheimer’s disease drives the dementia drugs market growth in coming years

According to Alzheimer’s Association, approximately 5.7 million people were living with dementia in 2018 within the United States. In addition, they projected that 13.9 million individuals aged 65 years or older will be diagnosed with Alzheimer’s disease or related dementias in the United States by 2060. According to World Health Organization worldwide, around 50 million people have dementia, and there are nearly 10 million new cases every year. In addition, government is spending high for developing the healthcare infrastructure in order to support the R&D activities along with availability of various business policies is influencing the growth of target market.

Global Dementia Drugs Market Dynamics

Market Drivers

• Increasing number of dementia cases
• Rising prevalence of Alzheimer’s in the world
• Growth in cases of chronic disorders
• Growing base of elderly population

Market Restraints

• Presence of strict regulatory framework
• Failure of investigational candidates in late stage

Market Opportunities

• Growing government funding and initiatives
• Introduction to innovative technologies

Dementia Drugs Market Report Coverage

Market	Dementia Drugs Market
Dementia Drugs Market Size 2021	USD 15.5 Billion
Dementia Drugs Market Forecast 2030	USD 32.3 Billion
Dementia Drugs Market CAGR During 2022 - 2030	8.7%
Dementia Drugs Market Analysis Period	2018 - 2030
Dementia Drugs Market Base Year	2021
Dementia Drugs Market Forecast Data	2022 - 2030
Segments Covered	By Drug Class, By Distribution Channel, And By Geography
Regional Scope	North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
Key Companies Profiled	Janssen Pharmaceuticals, Inc., Biogen Pharmaceuticals, Forest Laboratories, Inc., Eli Lilly and Company, Novartis AG, Sanofi S.A., AstraZeneca, F. Hoffmann-La Roche, Merck and Co., Inc., Valeant Pharmaceutical International, Eisai, Inc., Pfizer Inc., and Teva Pharmaceuticals Industries Ltd.
Report Coverage	Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis

Dementia Drugs Market Insights

Initiatives by the government and non-government agencies to establish a platform with a focus to treat patients suffering from dementia are increasing. In 2017 World Health Organization, established the Global Dementia Observatory, an international surveillance platform for policy-makers and researchers to facilitate monitoring and sharing of information on dementia policies, service delivery, epidemiology, and research.

However, factors such as high costs associated with R&D activities and stringent government regulations related to product approval are factors expected to hamper the growth of the global dementia drugs market. In addition, the lack of regulatory standards in a developing country is expected to challenge the growth of the target market.

High investment by the government for drug development, rapid technological advancements in drug discovery techniques, and players' approach to the introduction of innovative solutions are factors expected to create new opportunities for players operating in the target market. In addition, an increasing partnership between regional and international players is expected to support the revenue growth of the target market.

Dementia Drugs Market Segmentation

The worldwide dementia drugs market is split based on drug class, distribution channel, and geography.

Dementia Drugs Market By Drug Class

• MAO Inhibitors
• Glutamate Inhibitors
• Cholinesterase Inhibitors

According to our dementia drugs industry analysis, the MAO inhibitors sub-segment achieved a significant market share in 2021 and is likely to continue its trend during the forecasted timeframe from 2022 to 2030. Several studies have found that MAO inhibitors strengthen cognitive deficits and reverse A pathology by modulating amyloid precursor protein proteolytic cleavage and decreasing A protein fragments. As a result, MAO inhibitors may well be considered promising therapeutic agents for Alzheimer's disease.

Dementia Drugs Market By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

According to our dementia drugs market forecast, the hospital pharmacies is expected to generate a considerable market share from 2022 to 2030. On the other hand, the retail pharmacies are expected to witness faster growth in the target market. Increasing acceptance of over-the-counter drugs is one of the retail pharmacies market trend that is supporting the overall Alzheimer's disease  market growth.

Dementia Drugs Market Regional Outlook

North America

• U.S.
• Canada

Europe

• U.K.
• Germany
• France
• Spain
• Rest of Europe

Latin America

• Mexico
• Brazil
• Rest of Latin America

Asia-Pacific

• India
• Japan
• China
• Australia
• South Korea
• Rest of Asia-Pacific

The Middle East & Africa (MEA)

• Gulf Cooperation Council (GCC)
• South Africa
• Rest of the Middle East & Africa

Population Reference Bureau (PRB) Estimates 9 Million Americans Could Have Dementia by 2030

The market in North America is expected to account for significant revenue share owing to increasing number of patients suffering from chronic diseases. In addition, availability of advanced healthcare infrastructure and high investment by players for R&D activities are factors expected to support the growth of target market. Increasing focus on merger and acquisition activities in order to increase the business profit ratio and enhance the product portfolio is expected to support the growth of target market. However, the Asia-Pacific region is likely to attain a fastest growth rate in the coming years.

Dementia Drugs Market Players

The global market is high highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.

The global dementia drugs companies profiled in the report include Janssen Pharmaceuticals, Inc., Biogen Pharmaceuticals, Forest Laboratories, Inc., Eli Lilly and Company, Novartis AG, Sanofi S.A., AstraZeneca, F. Hoffmann-La Roche, Merck and Co., Inc., Valeant Pharmaceutical International, Eisai, Inc., Pfizer Inc., and Teva Pharmaceuticals Industries Ltd.

Players focus on enhancing the business presence in developing countries in order to enhance the business presence is expected to augment the growth of target market. In addition, focus on enhancing the business presence through strategic partnerships and product launches is expected to support the growth of target market.

In 2019, the FDA approved Rivastigmine (Exelon®), for mild-to-moderate Alzheimer’s as well as mild to moderate dementia associated with Parkinson’s disease.

In 2019, Biogen a global drug company submitted the application to Food and Drug Administration to approve an experimental drug, aducanumab, to treat people with mild cognitive impairment and the earliest signs of Alzheimer’s disease.

In 2016, Ajanta Pharma Limited launched anti-dementia Memantine Hydrochloride tablets in the US market. This is expected to help the company to enhance the customer base and strengthen its position in US market.

TABLE OF CONTENT